The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The Progress and Prospect of Zeolitic Imidazolate Frameworks in Cancer Therapy, Antibacterial Activity, and Biomineralization
Open accessAbstract
The progressive development of zeolitic imidazolate frameworks (ZIFs), as a subfamily of metal‐organic frameworks (MOFs), and their unique features, including tunable pore size, large surface area, high thermal stability, and biodegradability/biocompatibility, have made them attractive in the field of biomedicine, especially for drug delivery and biomineralization applications. The high porosity of ZIFs gives them the opportunity for encapsulating a high amount of therapeutic drugs, proteins, imaging cargos, or a combination of them to construct advanced multifunctional drug delivery systems (DDSs) with combined therapeutic and imaging capabilities. This review summarizes recent strategies on the design and fabrication of ZIF‐based nansystems and their exploration in the biomedical field. First, recent developments for the adjustment of particle size, functionality, and morphology of ZIFs are discussed, which are important for achieving optimized therapeutic/theranostic nanosystems. Second, recent trends on the application of ZIF nanocarriers for the loading of diverse cargos, including anticancer medicines, antibiotic drugs, enzymes, proteins, photosensitizers, as well as imaging and photothermal agents, are investigated in order to understand how multifunctional DDSs can be designed based on the ZIF nanoparticles to treat different diseases, such as cancer and infection. Finally, prospects on the future research direction and applications of ZIF‐based nanomedicines are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Brunner, T. J., Wick, P., Manser, P., Spohn, P., Grass, R. N., Limbach, L. K., Bruinink, A., & Stark, W. J. (2006) · Environmental Science & Technology · doi:10.1021/es052069i · Cited by 1,385
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501
Cheng, G., Li, W., Ha, L., Han, X., Hao, S., Wan, Y., Wang, Z., Dong, F., Zou, X., Mao, Y., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b03584 · Cited by 371
Cited by
MOF-enabled confinement and related effects for chemical catalyst presentation and utilization
Liu, J., Goetjen, T. A., Wang, Q., Knapp, J. G., Wasson, M. C., Yang, Y., Syed, Z. H., Delferro, M., Notestein, J. M., Farha, O. K., et al. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00968k · Cited by 386
Pettinari, C., Pettinari, R., Di Nicola, C., Tombesi, A., Scuri, S., & Marchetti, F. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214121 · Cited by 329
Rahmani, A., Maleki, A., Jafari, R., Rezaeejam, H., & Nadri, S. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00789e · Cited by 10
Self-citation
Metadata
- Authors
- Maleki, A., Shahbazi, M., Alinezhad, V., & Santos, H. A.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2020-05-07
- Volume
- 9
- Issue
- 12
- Pages
- e2000248-e2000248
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W3023144950
- Cited by
- 188
- References
- 8
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.